By Erin Coe ( January 16, 2008, 12:00 AM EST) -- The stakes are high for Merck & Co. and Schering-Plough Corp. as they face proposed class actions and a congressional inquiry over doubts of the effectiveness of their cholesterol drugs, Vytorin and Zetia, which account for a whopping $5 billion in annual sales....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.